Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
68.45
+0.73 (1.08%)
At close: Nov 20, 2026, 4:00 PM EST
67.65
-0.80 (-1.17%)
After-hours: Nov 20, 2026, 7:48 PM EST
Royalty Pharma Market Cap
Royalty Pharma has a market cap or net worth of $39.26 billion as of November 20, 2026. It is the 609th most valuable company in the world and the 288th biggest in the United States. Its market cap has increased by 137.77% in one year.
Market Cap
39.26B
Enterprise Value
47.31B
1-Year Change
137.77%
Global Rank
Country Rank
#288 United States
Category
ChartMarket Cap Chart
Since June 16, 2020, Royalty Pharma's market cap has increased from $15.76B to $39.26B, an increase of 149.12%. That is a compound annual growth rate of 15.25%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 30.50B | 84.73% |
| Dec 31, 2025 | 16.51B | 45.66% |
| Dec 31, 2024 | 11.33B | -9.30% |
| Dec 29, 2023 | 12.50B | -28.31% |
| Dec 30, 2022 | 17.43B | 1.85% |
| Dec 31, 2021 | 17.12B | -11.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Jun 16, 2020 (IPO) | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Moderna | 79.63B |
| argenx SE | 58.93B |
| BeOne Medicines AG | 46.10B |
| Revolution Medicines | 34.57B |
| Genmab | 32.46B |
| Roivant Sciences | 28.06B |
| Insmed | 26.28B |
| Incyte | 24.01B |